When tissue is no longer the issue: Tissue-agnostic cancer therapy comes of age

Shiuh Wen Luoh, Keith T. Flaherty

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Matching unique features of cancer types with effective therapies is a cornerstone of precision medicine. Clinical success has been seen in inhibiting specific molecular alterations that drive the growth of cancer cells and targeting molecules whose elevated expression is confined to cancer cells. In addition, cancer cells can have vulnerabilities induced by somatic mutations they carry; attacks on these vulnerabilities range from specific molecular alterations pointing to direct drug strategies to harnessing immune recognition of genetically altered epitopes produced by the cancer cells. Recent advances have found that the success of biomarker-driven cancer therapy may be relevant across sites of origin. For example, cancer types that show DNA mismatch repair deficiency, such as colon, biliary, and endometrial cancer, are more sensitive to immune checkpoint inhibition. Several large, ongoing clinical trials with a “basket” design are combining tumor tissue genomics with potential off-the-shelf therapies in drug development, and more tissue-agnostic biomarker therapies are reaching the bedside.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalAnnals of internal medicine
Issue number4
StatePublished - Aug 21 2018

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'When tissue is no longer the issue: Tissue-agnostic cancer therapy comes of age'. Together they form a unique fingerprint.

Cite this